Wegovy for Weight Loss Dunedin | Metabolic Confidence Programme
Science-led weight loss for people serious about long-term change.
If diet and exercise alone haven’t worked, Wegovy (semaglutide) might be the solution you’ve been looking for. Wegovy is a clinically proven, doctor-prescribed weight loss injection that helps regulate appetite and support long-term weight management.
At Dunedin Medical & Aesthetics Clinic, we offer personalised weight loss solutions, ensuring that Wegovy is the right fit for you. Book a consultation today to start your journey towards a healthier you!
Disclaimer
The information provided on this website regarding Wegovy (semaglutide) is for educational purposes only and should not be considered medical advice. Wegovy is a prescription medication and should only be used under the supervision of a qualified healthcare professional. Individual results may vary, and it may not be suitable for everyone. Before starting any weight loss program or medication, consult your healthcare provider to determine if it is appropriate for your specific needs and medical history. Always follow the advice and instructions provided by your healthcare professional.
Why Choose Dunedin Medical & Aesthetics Clinic?
At our clinic, we are committed to providing holistic and evidence-based weight management. Our experienced medical team understands that no two patients are the same, so we take the time to develop personalised plans that fit your lifestyle and health goals.
✅ NZ-Registered Doctors – Our team is led by highly qualified doctors with extensive experience in weight management.
✅ Personalised Care – Every consultation is customised to suit your individual needs and health status.
✅ Safe & Effective – We adhere to strict safety protocols to ensure your well-being, especially when prescribing medications such as Wegovy®.
✅ Comprehensive Medication Review – Our Clinical Pharmacist independently assesses your medications to rule out interactions with existing medicines or medical conditions.
What is Wegovy?
Wegovy® is a once-weekly weight loss injection containing semaglutide, a GLP-1 receptor agonist. It mimics your body’s natural satiety hormone to reduce hunger, regulate appetite, and support sustained weight loss.
It is indicated for adults with:
-
BMI ≥30 (obesity), or
-
BMI ≥27 with a weight-related health condition (e.g., PCOS, pre-diabetes)
How It Works
Step 1. Book an in-depth consultation with our clinical team (Doctor + Pharmacist review, lab tests, eligibility check).
Step 2. Begin the Metabolic Activation Phase (Wegovy titration), including monthly medication and clinical check-ins.
Step 3. Enter the Sustainable Control Phase with ongoing support, optional body composition scans, and a long-term plan that actually lasts.
Did you know?
In clinical trials, patients taking Wegovy (semaglutide 2.4 mg) alongside a reduced-calorie diet and increased physical activity lost an average of 15%–17% of their body weight over 68 weeks.
Some individuals lost up to 18% or more, particularly with continued treatment beyond one year.
Supporting Evidence:
-
STEP 1 Trial (Wilding et al., NEJM 2021): Average weight loss was 14.9% at 68 weeks.
-
STEP 5 Trial (Husain et al., Nat Med 2022): Over 104 weeks, patients maintained or slightly exceeded 17–18% weight loss.
See beyond the scale with quarterly Tanita scans.
Weight is just one piece of the puzzle. With our Tanita Body Composition Analysis, you’ll track what truly matters:
-
Visceral fat — the deep fat linked to metabolic risk
-
Muscle mass — to ensure you're losing fat, not strength
-
Metabolic age — an indicator of internal health, not just appearance
-
Hydration and segmental balance — for a holistic view of your progress
These scans are included every 12 weeks for in-clinic members, helping you stay motivated and focused — even when the number on the scale stalls.
Because sustainable weight loss is about body composition, not just body weight.
What’s Included in the Programme
🧪 Medical Consult & Lab Testing
Your journey begins with a comprehensive health assessment by our clinical pharmacist and doctor team. We review your medical history, current medications, and lifestyle factors — with blood tests included — to ensure Wegovy is safe and appropriate for you.
📦 Monthly Wegovy Supply
Once approved, you’ll receive your Wegovy prescription on a regular monthly schedule. For out-of-town patients, we manage temperature-safe, overnight cold chain delivery to non-rural addresses — so your medication arrives when and where you need it.
📉 Optional Body Composition Scans (Tanita)
Go beyond the number on the scale. Our in-clinic Tanita scans (offered quarterly) measure visceral fat, muscle mass, hydration, and metabolic age — giving you deeper insight into how your body is actually changing. A powerful motivator, especially when your weight plateaus.
🧑⚕️ Clinician Check-Ins & Progress Review
Every 12 weeks, you’ll meet with our team to assess your response to Wegovy, adjust goals, and troubleshoot challenges. These aren’t rushed pharmacy visits — they’re collaborative reviews designed to protect your safety and maximise long-term success.
🤝 Clinical Partnership, Not a One-Off Transaction
Metabolic Confidence is not a “weight loss product.” It’s a long-term programme, rooted in trust, evidence, and accountability. We’re not here to sell a script — we’re here to walk beside you as your metabolism resets, your appetite changes, and your confidence rebuilds.
What to Expect from Wegovy Metabolic Confidence Programme at DMAC
1️⃣ Initial Consultation – Comprehensive assessment with Dr. Lee to discuss your health history and weight loss goals.
2️⃣ Personalised Weight Loss Plan – Receive a tailored plan incorporating Wegovy, nutrition, and lifestyle recommendations.
3️⃣ Ongoing Monitoring & Support – Follow-up appointments to track progress, adjust dosage, and ensure optimal results.
📅 Book a Consultation Today! Limited slots available.
Take Control of Your Health Today
Ready to start your weight management journey? Book a consultation with our NZ-registered healthcare professionals today—whether in person or via telehealth, we provide expert guidance and personalised treatment plans to help you achieve sustainable, long-term results.
📞 Contact us now to schedule your consultation!
FAQs About Wegovy
Q: How much weight can I lose on Wegovy?
A: Clinical trials show that patients on Wegovy (2.4 mg) can lose an average of 15–17% of their body weight over 12–16 months, when combined with a reduced-calorie diet and increased physical activity. Some individuals may lose even more with continued treatment.
Q: How soon will I see results?
A: Many patients notice a reduction in appetite within the first few weeks. Significant weight loss typically becomes visible within 8–12 weeks, with continued improvements throughout the first year of treatment.
Q: Can I buy Wegovy over the counter in New Zealand?
A: No. Wegovy is a prescription-only medicine in New Zealand and requires a full clinical review to determine eligibility.
Q: What’s the difference between Wegovy and Ozempic?
A: Both contain semaglutide, a GLP-1 receptor agonist. However:
-
Wegovy is specifically approved for chronic weight management at a higher dose (2.4 mg)
-
Ozempic is approved for type 2 diabetes, not for weight loss use in NZ
Metabolic Confidence uses Wegovy as part of a structured, medically supervised weight programme — not off-label prescribing.
Think of Wegovy® as a structured, medically guided path to long-term metabolic health:
1. Losing Weight
Wegovy® (semaglutide 2.4 mg) is clinically proven to help patients lose up to 15–17% of their starting body weight over 12–16 months when combined with a reduced-calorie diet and regular physical activity.
This level of weight loss goes beyond appearance — it directly improves metabolic health, insulin sensitivity, and appetite regulation.
2. Keeping It Off
Obesity is a chronic, relapsing condition — and Wegovy is designed for long-term use. Staying on treatment helps maintain weight loss and prevents the common cycle of regain. Sustained improvements may include:
✔ Lower blood pressure
✔ Reduced triglycerides and LDL cholesterol
✔ Increased HDL (good) cholesterol
✔ Lowered risk of type 2 diabetes and cardiovascular disease
💡 Even modest, sustained weight loss improves outcomes. Research shows that every kilogram lost reduces systolic blood pressure by 1–2 mmHg, supporting heart health and longevity.
📞 Book a consultation today to find out if Wegovy is right for you — and learn how Metabolic Confidence can help you reset your biology, not just your weight.
Consumer Medicine Information (CMI)
Wegovy® is an unfunded prescription medicine - patient co-payment for medicine and healthcare professional fees apply.
Wegovy® FlexTouch® (semaglutide solution for injection).
Wegovy® FlexTouch® (semaglutide solution for injection). Available in the following dose forms: 0.25 mg (0.68 mg/mL), 0.5 mg (1.34 mg/mL), 1.0 mg (1.34 mg/mL), 1.7 mg (2.27 mg/mL) and 2.4 mg (3.2 mg/mL). Indication: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adult patients with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity; in adolescents ages 12 years and above with initial obesity* and body weight above 60 kg (*obesity (BMI ≥95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) – refer to full datasheet); as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease, with a BMI ≥27 kg/m2, and without established Type 1 or Type 2 diabetes. Treatment with Wegovy® should be re-evaluated and discontinued if adolescent patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or maximum tolerated dose. Dosage and administration: Administered subcutaneously once weekly at any time of day, with or without meals; starting dose 0.25 mg; increase to a maintenance dose of 2.4 mg over a 16-week period at 4 weekly intervals. In case of significant gastrointestinal symptoms, consider delaying dose escalation until symptoms have improved. If patients do not tolerate the 2.4 mg dose, the dose can be decreased to 1.7 mg weekly. Patients should re-escalate to the 2.4 mg dose if tolerated. Doses higher than 2.4 mg are not recommended. Must not be administered intravenously or intramuscularly. Contraindications: Hypersensitivity to semaglutide or any of its excipients. Warnings and precautions: Consider the risk of aspiration during general anaesthesia or deep sedation; dehydration in relation to gastrointestinal side effects in patients with impaired renal function may cause deterioration in renal function; there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure. Inform patients of the characteristic symptoms of acute pancreatitis, and discontinue if suspected; do not restart if confirmed. Exercise caution in patients with a history of pancreatitis. Not studied in patients: treated with other products for weight management; with Type 1 diabetes; with congestive heart failure New York Heart Association (NYHA) class IV. Limited experience in patients: aged 85 years or more; with inflammatory bowel disease; with diabetic gastroparesis; with severe renal impairment; with severe hepatic impairment. Must not be used as a substitute for insulin. Should not be used in combination with other GLP-1 products. Treatment in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia. The addition of Wegovy® in patients treated with insulin has not been evaluated. Patients with a history of diabetic retinopathy should be monitored for worsening. Not recommended for patients with uncontrolled or unstable diabetic retinopathy. When initiating treatment of semaglutide in patients treated with warfarin or other coumarin derivatives, frequent monitoring of INR is recommended. Pregnancy Category D. Not for use during pregnancy or breast-feeding. Interactions: Semaglutide delays gastric emptying, use with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption. Undesirable effects: Very Common (≥10%): nausea, vomiting, diarrhoea, constipation, abdominal pain, headache, fatigue. Common (≥1 to <10%): gastritis, gastroesophageal reflux disease, dyspepsia, eructation, flatulence, abdominal distension, dry mouth, dizziness, dysgeusia, dysaesthesia, cholelithiasis, hair loss, injection site reactions; in patients with Type 2 diabetes: hypoglycaemia, diabetic retinopathy. (April 2025)
1. Why am I using Wegovy® ?
Wegovy® contains the active ingredient semaglutide. Wegovy® is similar to a natural hormone called glucagonlike peptide-1 (GLP-1) that is released from the intestine after a meal. Wegovy® works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry and experience less craving for food. This will help you eat less food and reduce your body weight. Wegovy® is used for weight loss and weight maintenance in addition to diet and physical activity in adults, who have a BMI of 30 kg/m² or greater (obesity), or a BMI of 27 kg/m² and less than 30 kg/m² (overweight) and weight-related health problems. Wegovy® is used to reduce the risk of a heart disease related event in adults with a history of heart disease who do not have Type 1 or Type 2 diabetes and have a BMI of 27 kg/m² or greater. BMI (Body Mass Index) is a measure of your weight in relation to your height. Wegovy® is used together with diet and physical activity for weight management in adolescents aged 12 years and above, who have obesity and body weight >60 kg. As an adolescent patient, you should only continue using Wegovy if you have lost at least 5% of your BMI after 12 weeks on the 2.4 mg dose or maximum tolerated dose (see Section 4. How do I use Wegovy®?). Consult your doctor before you continue. Wegovy® is an injection that is used once a week.
2. What should I know before I use Wegovy?
Warnings Do not use Wegovy® if: You are allergic to semaglutide, or any of the ingredients listed at the end of this leaflet. Some of the symptoms of an allergic reaction may include: o redness, swelling, rash and itching at the injection site o rash, itching or hives on the skin o shortness of breath o wheezing or difficulty breathing o swelling of the face, lips, tongue or other parts of the body. Always check the ingredients to make sure you can use this medicine. Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes. It is after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering. It has expired or is damaged, return it to your pharmacist for disposal. The expiry date refers to the last day of that month. The use of Wegovy is not recommended if you: use other products for weight loss have type 1 diabetes have severe heart failure There is little experience with Wegovy in patients: of 85 years and older with severe stomach or gut problem which results in delayed stomach emptying (called gastroparesis), or if you have an inflammatory bowel disease. Please consult your doctor if one of the above applies to you. Check with your doctor if you: have any other medical conditions VV-LAB-125469 1.0 . Wegovy® FlexTouch® Consumer Medicine Information 3 take any medicines for any other condition. During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects? Pregnancy and breastfeeding Check with your doctor if you are pregnant or intend to become pregnant. This medicine should not be used during pregnancy, and for at least two months before a planned pregnancy because Wegovy® may harm your unborn child. Therefore, it is recommended to use contraception while using this medicine. If you wish to become pregnant, you should stop using this medicine at least two months in advance. If you become or are pregnant, think you may be pregnant or are planning to have a baby when using this medicine, talk to your doctor straight away, as your treatment will need to be stopped. Talk to your doctor if you are breastfeeding or intend to breastfeed. Do not use this medicine if you are breast-feeding, as it is unknown if it passes into breast milk. Food or liquid getting into lungs during anaesthesia Some patients taking medicines like Wegovy® have had problems with food or liquid from their stomach getting into their lungs while under general anaesthesia or deep sedation. Tell your healthcare professional that you are taking Wegovy® before you have a procedure that requires general anaesthesia or deep sedation. Effects on the digestive system During treatment with Wegovy®, you may feel sick (nausea), or be sick (vomiting), or have diarrhoea. These side effects can cause dehydration (loss of fluids). It is important that you drink enough fluids to prevent dehydration. This is especially important if you have kidney problems. Talk to your doctor if you have any questions or concerns. Inflammation of the pancreas If you have severe and on-going pain in the stomach area – see a doctor straight away as this could be a sign of an inflamed pancreas (acute pancreatitis). People with type 2 diabetes Do not use Wegovy® as a substitute for insulin. Low Blood Sugar (Hypoglycaemia) Taking a sulfonylurea (such as gliclazide or glimepiride) or an insulin with Wegovy® might increase the risk of getting low blood sugar levels (hypoglycaemia). Please see section 6 for the warning signs of low blood sugar levels. Your doctor may ask you to test your blood sugar levels. This will help your doctor decide if the dose of the sulfonylurea or insulin needs to be changed to reduce the risk of low blood sugar. Diabetic eye disease (retinopathy) Fast improvements in blood sugar control may lead to a temporary worsening of diabetic eye disease. If you have diabetic eye disease and experience eye problems while taking this medicine, talk to your doctor. Children and adolescents This medicine is not recommended in children and adolescents under 12 years as the safety and efficacy in this age group have not been established.
3. What if I am taking other medicines?
Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop. In particular, tell your doctor, pharmacist or nurse if you are using medicines containing the following: Warfarin or other similar medicines taken by mouth to reduce blood clotting (oral anti-coagulants). When you start treatment with e.g., warfarin or similar medicines, frequent blood testing to determine the ability of your blood to clot may be required. People with type 2 diabetes Your doctor may adjust the dose of your diabetes medicines to prevent you from getting low blood sugar. Do not mix Wegovy® up with other medicines that you inject (e.g., insulins). Do not use Wegovy® in combination with other medicines that contain GLP-1 receptor agonists (such as liraglutide, dulaglutide, exenatide or lixisenatide). Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect Wegovy®.
4. How do I use Wegovy® ?
How much to use Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure. Adults The recommended dose is 2.4 mg once weekly. Your treatment will start at a low dose which will be gradually increased over 16 weeks of treatment. When you first start using Wegovy®, the starting dose is 0.25 mg once weekly. Your doctor will instruct you to gradually increase your dose every 4 weeks until you reach the recommended dose of 2.4 mg once weekly. Once you reach the recommended dose of 2.4 mg, do not increase this dose further. You will be told to follow the table below. In case you are feeling very bothered by sickness (nausea) or by being sick (vomiting) talk with your doctor about adjusting your dose. VV-LAB-125469 1.0 . Wegovy® FlexTouch® Consumer Medicine Information 4 Dose escalation Weekly dose Week 1-4 0.25 mg Week 5-8 0.5 mg Week 9-12 1 mg Week 13-16 1.7 mg From week 17 2.4 mg Your doctor will assess your treatment on a regular basis. Adolescents (above 12 years of age) For adolescents, the same dose escalation schedule as for adults should be applied (see above). The dose should be increased until 2.4 mg (maintenance dose) or maximum tolerated dose has been reached. Weekly doses higher than 2.4 mg are not recommended. As an adolescent patient, you should regularly review your treatment goals with your doctor. Follow the instructions provided and use Wegovy® until your doctor tells you to stop. When to use Wegovy® You should use this medicine once a week and if possible, on the same day each week You can give yourself the injection at any time of the day – regardless of meals. If necessary, you can change the day of your weekly injection of this medicine as long as it has been at least 3 days since your last injection. After selecting a new dosing day, continue with once a week dosing. How Wegovy® is given Wegovy® is given as an injection under the skin (subcutaneous injection). Do not inject it into a vein or muscle. The best places to give the injection are the fronts of your upper arm, upper legs or stomach. Before you use the pen for the first time, ask your doctor, pharmacist or nurse how to use it. Follow the detailed instructions on how to inject Wegovy® FlexTouch® in the instructions for use supplied with the product. These instructions are also available via the following hyperlink https://medsinfo.com.au/media/noiwegof If you forget to use Wegovy® If you forgot to inject a dose and: it is 5 days or less since you should have used Wegovy®, use it as soon as you remember. Then inject your next dose as usual on your scheduled day. it is more than 5 days since you should have used Wegovy®, skip the missed dose. Then inject your next dose as usual on your next scheduled day. Do not take a double dose to make up for a forgotten dose. If you use too much Wegovy® Talk to your doctor straight away. You may get side effects such as feeling sick (nausea), being sick (vomiting) or have diarrhoea, which may cause dehydration (loss of fluids). If you think that you have used too much Wegovy®, you may need urgent medical attention. You should immediately: phone the Poisons Information Centre (by calling 13 11 26 in Australia or 0800 764766 in New Zealand), or contact your doctor, or go to the Emergency Department at your nearest hospital. You should do this even if there are no signs of discomfort or poisoning.
5. What should I know while using Wegovy® ?
Things you should do Tell your doctor or pharmacist if you are travelling. Ask them for a letter explaining why you are taking injecting devices with you. Each country you visit will need to see this letter, so you should take several copies. You may not be able to get Wegovy® FlexTouch® in the country you are visiting. Remind any doctor, dentist or pharmacist you visit that you are using Wegovy®. Things you should not do Do not stop using this medicine without talking to your doctor. Do not use this medicine if you think it has been frozen or exposed to excessive heat. Do not use this medicine to treat any other complaints unless your doctor tells you to. Do not give your medicine to anyone else, even if they have the same condition as you. Do not share your pen with anyone else. Do not use this medicine after the expiry date which is stated on the pen label and carton after ‘EXP’. The expiry date refers to the last day of that month. Driving or using machines Be careful before you drive or use any machines or tools until you know how Wegovy® affects you. Wegovy® is unlikely to affect your ability to drive and use machines. Some patients may feel dizzy when taking Wegovy® mainly during the first 4 months of treatment (see section 6). If you feel dizzy be extra careful while driving or using machines. If you need any further information, talk to your doctor, pharmacist or nurse. People with type 2 diabetes If you use this medicine in combination with a sulfonylurea or insulin, low blood sugar (hypoglycaemia) may occur which may reduce your ability to concentrate. Avoid VV-LAB-125469 1.0 . Wegovy® FlexTouch® Consumer Medicine Information 5 driving or using machines if you get any signs of low blood sugar. See section 2 for information on increased risk of low blood sugar and section 6 for the warning signs of low blood sugar. Looking after your medicine Store in a refrigerator (2°C – 8°C). Do not freeze. Keep away from the cooling element. Wegovy® can be taken out of the refrigerator for up to 6 weeks at a temperature below 30°C. Always store the pen in the original carton in order to protect from light. Do not use this medicine if you notice that the solution is not clear and colourless. Keep it where young children cannot reach it. When to discard your medicine Discard the Wegovy® FlexTouch® pen you are using after 6 weeks even if there is still some medicine left in it. Dispose of used needles safely into a yellow plastic sharps container. Getting rid of any unwanted medicine If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal. Do not use this medicine after the expiry date. The expiry date refers to the last day of that month.
6. Are there any side effects?
All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention. See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects. Less serious side effects Less serious side effects What to do Very common: may affect more than 1 in 10 people: headache feeling sick (nausea) being sick (vomiting) diarrhoea constipation stomach pain. feeling weak or tired – these usually go away over time. Common: may affect up to 1 in 10 people: feeling dizzy upset stomach or indigestion burping gas (flatulence) bloating of the stomach Speak to your doctor if you have any of these less serious side effects and they worry you. Less serious side effects What to do inflamed stomach ('gastritis') – the signs include stomach ache, feeling sick (nausea) or being sick (vomiting) reflux or heartburn – also called 'gastro-oesophageal reflux disease' dry mouth gallstones hair loss injection site reactions unpleasant, abnormal or altered taste sensation change in skin sensation low blood sugar (hypoglycaemia) in patients with diabetes. Uncommon: may affect up to 1 in 100 people: fast heartbeat increase in pancreas blood test results a delay in the emptying of the stomach. Hypoglycaemia The warning signs of low blood sugar may come on suddenly. They can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating or shaking. Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs. Low blood sugar is more likely to happen if you also take a sulfonylurea or insulin. Your doctor may reduce your dose of these medicines before you start using this medicine. Serious side effects Serious side effects What to do Complications of diabetic eye disease (diabetic retinopathy). If you have diabetes you should inform your doctor if you experience eye problems, such as changes in vision, during treatment with this medicine. Common: may affect up to 1 in 10 people Inflamed pancreas (acute pancreatitis). Signs of inflamed pancreas may include severe and long-lasting pain Call your doctor straight away, or go straight to the Accident and Emergency Department at your nearest hospital if you notice any of these serious side effects. VV-LAB-125469 1.0 . Wegovy® FlexTouch® Consumer Medicine Information 6 Serious side effects What to do in your stomach, with or without vomiting. You may feel the pain from your abdomen to your back. You should see your doctor immediately if you experience such symptoms. Uncommon: may affect up to 1 in 100 people Severe allergic reactions (anaphylactic reactions). You should seek immediate medical help and inform your doctor straight away if you get symptoms such as breathing problems, swelling of face, and throat, wheezing, fast heartbeat, pale and cold skin, feeling dizzy or weak. Rare: may affect up to 1 in 1,000 people Bowel obstruction A severe form of constipation with additional symptoms such as stomach ache, bloating, vomiting etc. Not known: frequency cannot be estimated from the available data. Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell. Other side effects not listed here may occur in some people. Reporting side effects After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. If you are in New Zealand, you can report side effects at https://pophealth.my.site.com/carmreportnz/s/. By reporting side effects, you can help provide more information on the safety of this medicine. Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.
7. Product details
This medicine is only available with a doctor's prescription. What Wegovy® FlexTouch® contains Active ingredient (main ingredient) semaglutide Other ingredients (inactive ingredients) dibasic sodium phosphate dihydrate propylene glycol phenol water for injections sodium hydroxide/hydrochloric acid (for pH adjustment) Potential allergens Nil Wegovy® FlexTouch® contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free’. Do not take this medicine if you are allergic to any of these ingredients. What Wegovy® FlexTouch® looks like Wegovy® FlexTouch® is a clear and colourless solution for injection in a pre-filled disposable pen. Each pen contains four doses. The pack size of each strength of Wegovy® FlexTouch® contains 1 pre-filled pen and 4 disposable NovoFine® Plus® needles. Wegovy® FlexTouch® 0.25 mg solution for injection (Aust R 424390) One mL of solution contains 0.68 mg of semaglutide. One pre-filled pen contains 1.0 mg semaglutide in 1.5 mL solution. Wegovy® FlexTouch® 0.5 mg solution for injection (Aust R 424391) One mL of solution contains 1.34 mg of semaglutide. One pre-filled pen contains 2.0 mg semaglutide in 1.5 mL solution. Wegovy® FlexTouch® 1 mg solution for injection (Aust R 424392) One mL of solution contains 1.34 mg of semaglutide. One pre-filled pen contains 4.0 mg semaglutide in 3 mL solution. Wegovy® FlexTouch® 1.7 mg solution for injection (Aust R 424393) One mL of solution contains 2.27 mg of semaglutide. One pre-filled pen contains 6.8 mg semaglutide in 3 mL solution. Wegovy® FlexTouch® 2.4 mg solution for injection (Aust R 424394) One mL of solution contains 3.2 mg of semaglutide. One pre-filled pen contains 9.6 mg of semaglutide in 3 mL solution. Who distributes Wegovy® Wegovy® is supplied in Australia by: Novo Nordisk Pharmaceuticals Pty. Ltd. Level 10 118 Mount Street North Sydney NSW 2060 Wegovy® is supplied in New Zealand by: Novo Nordisk Pharmaceuticals Ltd. PO Box 51-268 Pakuranga VV-LAB-125469 1.0 . Wegovy® FlexTouch® Consumer Medicine Information 7 Auckland New Zealand. Wegovy®, FlexTouch® and NovoFine® are registered trademarks of Novo Nordisk A/S. © 2024 Novo Nordisk A/S Further information For further information call Novo Nordisk Medical Information on 1800 668 626 (Australia) or 0800 733 737 (New Zealand). www.novonordisk.com.au www.novonordisk.co.nz WegovyCare® is a free support program. To find out more go to: wegovycare.com.au The Patient Support Program is not authorised or approved by the Australian regulator of medicines, the TGA. Always check the following websites to ensure you are reading the most recent version of the Wegovy® FlexTouch® consumer medicine information: www.novonordisk.com.au (AU) https://www.ebs.tga.gov.au/ (AU) www.novonordisk.co.nz (NZ) https://www.medsafe.govt.nz/medicines/infosearch.asp (NZ)